A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation-Reference-Cited by-同舟云学术

A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation

Published:2021-05-06 Issue:6 Volume:193 Page:1203-1212
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Willekens Guido¹²,Studt Jan‐Dirk³,Mendez Adriana⁴,Alberio Lorenzo⁵,Fontana Pierre⁶,Wuillemin Walter A.⁷,Schmidt Adrian⁸,Graf Lukas⁹^ORCID,Gerber Bernhard¹⁰^ORCID,Bovet Cedric²,Sauter Thomas C.¹¹,Nagler Michael²¹²^ORCID

Affiliation:

1. Department of Epidemiology Maastricht University Maastricht the Netherlands

2. Department of Clinical Chemistry, Inselspital Bern University HospitalUniversity of Bern BernSwitzerland

3. Division of Medical Oncology and Hematology University Hospital Zurich ZurichSwitzerland

4. Department of Laboratory Medicine Kantonsspital Aarau AarauSwitzerland

5. Service and Central Laboratory of Hematology Lausanne University Hospital (CHUV) and University of Lausanne LausanneSwitzerland

6. Division of Angiology and Hemostasis Geneva University Hospital GenevaSwitzerland

7. Division of Hematology and Central Hematology Laboratory Cantonal Hospital of LucerneUniversity of Bern BernSwitzerland

8. Institute of Laboratory Medicine and Clinic of Medical Oncology and Hematology City Hospital Waid and Triemli ZurichSwitzerland

9. Cantonal Hospital of St Gallen St GallenSwitzerland

10. Clinic of Hematology Oncology Institute of Southern Switzerland BellinzonaSwitzerland

11. Department of Emergency Medicine InselspitalBern University Hospital BernSwitzerland

12. Department of Hematology InselspitalBern University Hospital Bern Switzerland

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17470

Reference31 articles.

1. How I manage patients with anticoagulation‐associated bleeding or urgent surgery;Sauter TC;Swiss Med Wkly,2018

2. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants

3. Exploring indications for the use of direct oral anticoagulants and the associated risks of major bleeding;Milling TJ;Am J Manag Care,2017

4. Incidence of Oral Anticoagulant–Associated Intracerebral Hemorrhage in the Netherlands

5. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assays for Monitoring Apixaban and Rivaroxaban in Emergency Settings, State-of-the-Art Routine Analysis, and Volumetric Absorptive Microsamples Deliver Discordant Results;Diagnostics;2024-09-02

2. Development and validation of an ultrafast method of quantification of rivaroxaban in human serum using laser diode thermal desorption coupled to triple quadrupole mass spectrometry;Rapid Communications in Mass Spectrometry;2024-07-11

3. Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH;Journal of Thrombosis and Haemostasis;2024-07

4. Challenges to Laboratory Monitoring of Direct Oral Anticoagulants;Clinical and Applied Thrombosis/Hemostasis;2024-01

5. A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban;Thrombosis Research;2024-01